Acer Therapeutics Inc. (ACER): Price and Financial Metrics


Acer Therapeutics Inc. (ACER): $2.88

-0.04 (-1.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACER Stock Price Chart Interactive Chart >

Price chart for ACER

ACER Price/Volume Stats

Current price $2.88 52-week high $5.84
Prev. close $2.92 52-week low $2.15
Day low $2.83 Volume 89,700
Day high $2.91 Avg. volume 814,713
50-day MA $2.85 Dividend yield N/A
200-day MA $2.94 Market Cap 41.21M

Acer Therapeutics Inc. (ACER) Company Bio


Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.


ACER Latest News Stream


Event/Time News Detail
Loading, please wait...

ACER Latest Social Stream


Loading social stream, please wait...

View Full ACER Social Stream

Latest ACER News From Around the Web

Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.

Here is What Hedge Funds Think About Acer Therapeutics Inc. (ACER)

No summary available.

Insider Monkey | June 13, 2021

Acer Therapeutics (ACER) Receives a Hold from Needham

Needham analyst Serge Belanger maintained a Hold rating on Acer Therapeutics (ACER) today. The companys shares closed last Friday at $3. The post Acer Therapeutics (ACER) Receives a Hold from Needham appeared first on Smarter Analyst .

Smarter Analyst | June 11, 2021

Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA Meeting

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical

Wallstreet:Online | June 10, 2021

Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakthrough designation NEWTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious

Yahoo | June 10, 2021

What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | June 9, 2021

Read More 'ACER' Stories Here

ACER Price Returns

1-mo -0.35%
3-mo -26.15%
6-mo 11.63%
1-year -10.00%
3-year -85.04%
5-year -92.70%
YTD 9.92%
2020 -34.66%
2019 -80.07%
2018 45.27%
2017 45.45%
2016 -66.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0646 seconds.